Pancreatic Cancer Research

ResearcherNational and Kapodistrian University of AthensActive in the last 2 years

Panagiotis Sarantis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5848-7905; OpenAlex author ID A5015892000. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 2 papers · 2021: 3 papers · 2022: 5 papers · 2023: none · 2024: 2 papers

Papers 12

  1. l-Securinine Induces ROS-Dependent Apoptosis on Pancreatic Cancer Cells via the PI3K/AKT/mTOR Signaling Pathway. First author DOI 10.1002/jbt.70036↗
  2. A Current Synopsis of the Emerging Role of Extracellular Vesicles and Micro-RNAs in Pancreatic Cancer: A Forward-Looking Plan for Diagnosis and Treatment. Co-author DOI 10.3390/ijms25063406↗
  3. The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.thromres.2022.02.004↗
  4. Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer? Co-author DOI 10.21873/invivo.12736↗
  5. Targeting autophagy in pancreatic cancer: The cancer stem cell perspective. Co-author DOI 10.3389/fonc.2022.1049436↗
  6. The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches. Co-author DOI 10.3390/genes13101868↗
  7. Pancreatic Cancer Prognosis, Malnutrition Risk, and Quality of Life: A Cross-Sectional Study. Co-author DOI 10.3390/nu14030442↗
  8. Combinatorial Treatment of Tinzaparin and Chemotherapy can Induce a Significant Antitumor Effectin Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-551892/v1↗
  9. The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. Co-author DOI 10.3390/cancers13122884↗
  10. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer. Co-author DOI 10.3390/ijms22137053↗
  11. Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights. First author DOI 10.3390/nu12061543↗
  12. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. Co-author DOI 10.4251/wjgo.v12.i2.173↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michalis V. Karamouzis · 9 shared papers, 2020–2024 · strength 1.54
  2. Evangelos Koustas · 8 shared papers, 2020–2024 · strength 1.19
  3. Athanasios G. Papavassiliou · 4 shared papers, 2020–2021 · strength 0.52
  4. Pavlos Papakotoulas · 3 shared papers, 2021 · strength 0.36
  5. Evangelos S. Felekouras · 3 shared papers, 2021 · strength 0.36
  6. Alexandros Papalampros · 3 shared papers, 2021 · strength 0.36
  7. Dimitriοs Schizas · 3 shared papers, 2021 · strength 0.36
  8. Kalliopi‐Anna Poulia · 2 shared papers, 2020–2022 · strength 0.35
  9. Eleni-Myrto Trifylli · 2 shared papers, 2022–2024 · strength 0.34
  10. Nikolaos Garmpis · 2 shared papers, 2022 · strength 0.27
  11. Christos Damaskos · 2 shared papers, 2022 · strength 0.27
  12. Stamatios E Theocharis · 2 shared papers, 2021 · strength 0.25
  13. Efstathios Antoniou · 2 shared papers, 2021–2022 · strength 0.23
  14. Ioanna A. Anastasiou · 1 shared paper, 2024 · strength 0.21
  15. Nikolaοs Tentolouris · 1 shared paper, 2024 · strength 0.21
  16. Melanie J. Deutsch · 1 shared paper, 2024 · strength 0.19
  17. Dimitrios Troumpoukis · 1 shared paper, 2022 · strength 0.17
  18. Kostas Palamaris · 1 shared paper, 2022 · strength 0.17
  19. Ioannis Serafimidis · 1 shared paper, 2022 · strength 0.17
  20. Gregory P. Kouraklis · 1 shared paper, 2022 · strength 0.12
  21. Georgios Fotios Samelis · 1 shared paper, 2021 · strength 0.11
  22. Georgios Charalambos Sotiropoulos · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.